Marco Siano
Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
Siano M, Licitra L, Locati L, Miceli R, Granata R, Bergamini C, Alfieri S, Cau M, Resteghini C, Infante G, Bossi P. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncol 2017; 69:33-37.
09.04.2017Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
09.04.2017Oral Oncol 2017; 69:33-37
Siano Marco, Licitra Lisa, Locati Laura, Miceli Rosalba, Granata Roberta, Bergamini Cristiana, Alfieri Salvatore, Cau Maria Chiara, Resteghini Carlo, Infante Gabriele, Bossi Paolo
Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients
Siano M (2016). Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients.
11.10.2016Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients
11.10.2016-
Siano Marco
Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
Siano M (2016). Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting.
11.10.2016Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
11.10.2016-
Siano Marco
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Bossi P, Canevari S, Licitra L, Locati L, Pilotti S, Perrone F, Cortelazzi B, Marchesi E, Giannoccaro M, Favales F, Sponghini A, Cossu Rocca M, Siano M, Bergamini C, De Cecco L. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clin Cancer Res 2016; 22:3961-70.
26.02.2016Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
26.02.2016Clin Cancer Res 2016; 22:3961-70
Bossi Paolo, Canevari Silvana, Licitra Lisa, Locati Laura D, Pilotti Silvana, Perrone Federica, Cortelazzi Barbara, Marchesi Edoardo, Giannoccaro Marco, Favales Federica, Sponghini Andrea P, Cossu Rocca Maria, Siano Marco, Bergamini Cristiana, De Cecco Loris
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
Dummer R, Guckenberger M, Najafi Y, von Moos R, Mihic-Probst D, Michielin O, Braun R, Lindenblatt N, Hunger R, Siano M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016; 146:w14279.
22.02.2016The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
22.02.2016Swiss Med Wkly 2016; 146:w14279
Dummer Reinhard, Guckenberger Merlin, Najafi Yousef, von Moos Roger, Mihic-Probst Daniela, Michielin Oliver, Braun Ralph, Lindenblatt Nicole, Hunger Robert E, Siano Marco, Arnold Andreas
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
01.01.2016Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
01.01.2016J Immunother 2016; 39:379-382
Diem Stefan, Goldinger Simone M, Urner-Bloch Ursula, Siano Marco, Dummer Reinhard, Speiser Daniel E, Maillard Samia A, Rüesch Reinhard, Keller Fabienne, Flatz Lukas
Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom
Zürrer-Härdi U, Siano M, Broglie Däppen M. Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom. Schweiz. Krebsbulletin 2015; 1:98-101.
09.11.2015Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom
09.11.2015Schweiz. Krebsbulletin 2015; 1:98-101
Zürrer-Härdi Ursina, Siano Marco, Broglie Däppen Martina
Thyroid cancers: which molecular markers are relevant?
Siano M (2015). Thyroid cancers: which molecular markers are relevant?.
10.10.2015Thyroid cancers: which molecular markers are relevant?
10.10.2015DGHO 2015
Siano Marco
Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB)
Siano M (2015). Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB). Präsentiert bei: DGHO 2015, Basel
10.10.2015Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB)
10.10.2015DGHO 2015
Siano Marco
Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre
Siano M (2015). Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre. Präsentiert bei: DGHO 2015, -
10.10.2015Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre
10.10.2015DGHO 2015
Siano Marco
Site of metastatic disease influences adenoid cystic cancer (ACC) patients’ outcome
Cau M, Alfieri S, Siano M (2015). Site of metastatic disease influences adenoid cystic cancer (ACC) patients’ outcome.
09.10.2015Site of metastatic disease influences adenoid cystic cancer (ACC) patients’ outcome
09.10.2015AIOM
Cau MC, Alfieri S, Siano Marco
Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC)
Siano M (2015). Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC).
29.09.2015Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC)
29.09.2015ESMO 2015
Siano Marco
Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis
Siano M, Resteghini c, Licitra L, Bossi P (2015). Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis.
29.09.2015Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis
29.09.2015ESMO 2015
Siano Marco, Resteghini c, Licitra L, Bossi P
Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC)
Siano M (2015). Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC).
28.09.2015Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC)
28.09.2015ESMO 2015
Siano Marco
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
Feilchenfeldt J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano M, Grabsch H, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer 2015; 113:716-21.
27.08.2015Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
27.08.2015Br J Cancer 2015; 113:716-21
Feilchenfeldt J, Jochum Wolfram, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano Marco, Grabsch H I, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S
Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival
Siano M (2015). Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival.
02.06.2015Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival
02.06.2015ASCO 2015
Siano Marco
Das Adenoidzystische-Karzinom
AC V, Siano M, Broglie Däppen M, Toepfer M, Stöckli S. Das Adenoidzystische-Karzinom. info@onkologie.ch 2015; 1:10-12.
01.01.2015Das Adenoidzystische-Karzinom
01.01.2015info@onkologie.ch 2015; 1:10-12
AC Volck, Siano Marco, Broglie Däppen Martina, Toepfer Michael, Stöckli Sandro
Antiemese und Tumormedikation
Zürrer-Härdi U, Siano M, Blum D. Antiemese und Tumormedikation. info@onkologie.ch 2015; 1:20-26.
01.01.2015Antiemese und Tumormedikation
01.01.2015info@onkologie.ch 2015; 1:20-26
Zürrer-Härdi Ursina, Siano Marco, Blum David
Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag
Siano M. Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag. Leading Opinions Hämatologie / Onkologie 2015; 4
01.01.2015Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag
01.01.2015Leading Opinions Hämatologie / Onkologie 2015; 4
Siano Marco
Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia
Litschel R, Siano M, Tasman A, Cogliatti S. Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia. Allergy Rhinol (Providence) 2015; 6:191-4.
01.01.2015Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia
01.01.2015Allergy Rhinol (Providence) 2015; 6:191-4
Litschel Ralph, Siano Marco, Tasman Abel-Jan, Cogliatti Sergio B.